S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

InMed Pharmaceuticals (INM) Institutional Ownership

$0.41
0.00 (0.00%)
(As of 02/23/2024 ET)

Institutional Ownership Changes (13F Filings) for InMed Pharmaceuticals (NASDAQ:INM)

Current
Institutional Ownership
Percentage
0.47%
Number of
Institutional Buyers
(last 12 months)
2
Total
Institutional Inflows
(last 12 months)
$169,382.69
Number of
Institutional Sellers
(last 12 months)
0
Get INM Insider Trade Alerts

Want to know when executives and insiders are buying or selling InMed Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Skip Chart & View Institutional Buying and Selling Data

INM Institutional Buying and Selling by Quarter


InMed Pharmaceuticals Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/13/2024Armistice Capital LLC205,968$86K0.0%N/A3.916%
5/12/2023Renaissance Technologies LLC77,500$84K0.0%N/A2.329%
2/15/2023Virtu Financial LLC17,724$36K0.0%N/A1.886%
2/15/2023Armistice Capital LLC97,163$0.20M0.0%+8.0%10.336%
11/14/2022Armistice Capital LLC90,000$0.59M0.0%-90.6%9.605%
11/10/2022UBS Group AG5,797$38K0.0%N/A0.617%
5/17/2022Empery Asset Management LP61,741$58K0.3%N/A0.437%
8/17/2021Armistice Capital LLC890,000$2.83M0.1%+278.7%9.954%
8/12/2021Penserra Capital Management LLC19,912$49K0.0%N/A0.223%
5/21/2021Citadel Advisors LLC17,211$57K0.0%N/A0.214%
5/18/2021Citadel Advisors LLC17,211$57K0.0%N/A0.214%
5/17/2021Armistice Capital LLC235,000$0.78M0.0%N/A2.919%
1/29/2021Creative Planning10,990$36K0.0%N/A0.157%
(Data available from 1/1/2016 forward)













INM Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of INM shares?

During the previous two years, the following institutional investors and hedge funds held shares of InMed Pharmaceuticals shares: Armistice Capital LLC ($86K), Renaissance Technologies LLC ($84K), Empery Asset Management LP ($58K), and UBS Group AG ($38K), Virtu Financial LLC ($36K).Learn more on INM's institutional investors.

What percentage of InMed Pharmaceuticals stock is owned by institutional investors?

0.47% of InMed Pharmaceuticals stock is owned by institutional investors. Learn more on INM's institutional investor holdings.

Which institutional investors have been buying InMed Pharmaceuticals stock?

The following institutional investors have purchased InMed Pharmaceuticals stock in the last 24 months: Armistice Capital LLC ($0.21M), Renaissance Technologies LLC ($77.50K), Empery Asset Management LP ($61.74K), Virtu Financial LLC ($17.72K), and UBS Group AG ($5.80K).

How much institutional buying is happening at InMed Pharmaceuticals?

Institutional investors have bought a total of 375,893 shares in the last 24 months. This purchase volume represents approximately $1.71M in transactions.

Which InMed Pharmaceuticals major shareholders have been selling company stock?

The following institutional investors have sold InMed Pharmaceuticals stock in the last 24 months: Armistice Capital LLC ($0.87M).

How much institutional selling is happening at InMed Pharmaceuticals?

Institutional investors have sold a total of 866,118 shares in the last 24 months. This volume of shares sold represents approximately $5.71M in transactions.


This page (NASDAQ:INM) was last updated on 2/23/2024 by MarketBeat.com Staff